You cannot get a BPC-157 prescription filled through the ordinary pharmacy system because there is no approved BPC-157 drug to fill, and a compounding pharmacy has no federal pathway to make one. That is a statement about the supply chain, not about any single clinician. A prescriber can write almost anything on a pad, but a licensed pharmacy needs a lawful source for the drug it dispenses.
This page walks through that gap in the order a buyer runs into it: the drug approval question, the compounding question, what FDA said about BPC-157 in 2026, and what the human studies actually contain. For the broader picture of which peptides can be prescribed at all, see whether peptides are legal.
Step one: there is no approved product
Most prescriptions are filled with a manufactured drug that FDA approved. BPC-157 has never been through that process, so no manufacturer sells an approved version a pharmacy could stock. That leaves compounding, where a pharmacist mixes a drug for a named patient from raw ingredients called bulk drug substances.
Step two: the compounding rules shut the second door
Section 503A of the Federal Food, Drug, and Cosmetic Act sets the conditions a pharmacy compounding under a prescription must meet [3]. One condition concerns the raw ingredient. It must meet a United States Pharmacopeia monograph if one exists, or be a component of an FDA-approved drug, or appear on a list FDA develops by regulation, known as the 503A Bulks List [3].
BPC-157 has no approved drug to be a component of, and it is not on the Bulks List. While FDA works through nominations, it also keeps interim categories. Substances in Category 1 are under evaluation and covered by an interim policy, and BPC-157 is not in Category 1 [1]. It had been in Category 2, the category for substances raising significant safety risks, until the nominators withdrew their nominations [2].
This site's register, last checked in September 2026, files BPC-157 as a peptide no pharmacy may compound: it sits on none of FDA's 503A lists. A compounder that uses it anyway is outside the conditions that give compounded drugs their exemption from the approval rules. This is why the reader who asks a telehealth clinic for BPC-157 usually hears no, or is offered a different peptide instead.
What FDA told its advisory committee in 2026
On April 16, 2026, FDA announced that its Pharmacy Compounding Advisory Committee would discuss BPC-157 on July 23, 2026, as a candidate for the Bulks List [3]. The use FDA evaluated was ulcerative colitis. The nomination had also named Crohn's disease, celiac disease and tendonitis, but FDA did not evaluate those because the nomination lacked the information needed to do so [4].
FDA's briefing document for that meeting proposed not adding BPC-157, in either its free base or acetate form, to the list [4]. It gave four reasons. The substance is not well characterized chemically, and there is little information on its safety profile and immunogenicity risk. The evidence is insufficient to judge whether it treats ulcerative colitis, and approved drugs for that disease already exist [4].
The committee disagreed with FDA. At the July meeting it voted to recommend adding BPC-157 to the Bulks List, alongside KPV, TB-500, MOTS-c, Epitalon and Semax [7]. The BPC-157 vote was 8 to 6, with one abstention [9]. STAT described the panel's vote as narrow [8].
That vote is a recommendation and does not bind FDA [7]. FDA's own briefing says it will not issue a final determination until the committee's input has been considered and its reviews are finalized [4]. The HHS Secretary must still formally approve an addition, and pharmacies may not compound BPC-157 until final rulemaking is in place [7]. BPC-157 is not on the 503A Bulks List today.
What the human studies contain
FDA's search of PubMed and Embase found five clinical studies that used BPC-157 [4]. The table lists them the way the briefing document summarizes them. These are the amounts each study used, recorded as findings about the studies, and none of them is a dose anyone has shown to be safe or effective.
| What the study gave | Who received it |
|---|---|
| Up to 2 mg/kg rectal enema, once daily for 8 days | 24 healthy subjects |
| 80 mg rectal enema, once daily for 2 weeks | About 26 people with ulcerative colitis |
| 2 to 4 mg injected into the knee, 1 or 2 doses | 17 people with knee pain |
| 10 mg injected into the bladder, one procedure | 12 people with interstitial cystitis |
| 10 mg IV on day 1, then 20 mg IV on day 2 | 2 healthy subjects |
FDA noted that no serious adverse events appear to have been reported, and then listed the limits: short durations, small samples, exploratory doses and little safety detail [4]. It found no human pharmacokinetic data at all after oral, subcutaneous, nasal or transdermal use, which are the routes buyers usually ask about [4].
The intravenous study is a good illustration of the scale. It enrolled two people, a 58-year-old man and a 68-year-old woman who had both received intravenous BPC-157 before, at a private clinic in Florida [6]. The authors reported no measurable effect on the blood markers they tested and no side effects [6]. Two participants cannot detect an uncommon harm, whatever the result.
An independent review from 2025 reached the same place. It described broad support for BPC-157 in animal models, called the human data “extremely limited,” and concluded that it should be considered investigational until well-designed trials exist [5].
What this means if you were hoping to buy it
The legal path to a prescribed peptide runs through an approved drug or a lawfully compounded one, and BPC-157 has neither today. Products sold online as BPC-157 outside a pharmacy are usually labeled for research, which is a separate problem covered in what research use only means. The peptides that can be prescribed, and what a month of each costs, are on the price boards.
If a clinic offers you BPC-157 anyway, one question sorts out most of it: which licensed pharmacy will fill this, and under which part of the compounding law? A clinic that cannot name both is telling you something about the product. For how a legitimate peptide visit and pharmacy fill normally work, see how online peptide therapy works, and the methodology page explains which compounds this site will price at all.